Dextroamphetamine Saccharate | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Dextroamphetamine Saccharate
US Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Dextroamphetamine Saccharate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

8 API Suppliers, 8 USDMF, 7 NDC API, 4 Listed Suppliers, $ API Reference Price

8 API Suppliers
8 USDMF
7 NDC API
4 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

FINISHED DOSAGE FORMULATIONS

273 FDF Dossiers, 273 FDA Orange Book

273 FDF Dossiers
273 FDA Orange Book

DRUG PRODUCT COMPOSITIONS

CAPSULE, EXTENDED RELEASE;ORAL - 1.25MG;1.25MG;1.25MG;1.25MG, CAPSULE, EXTENDED RELEASE;ORAL - 2.5MG;2.5MG;2.5MG;2.5MG, CAPSULE, EXTENDED RELEASE;ORAL - 3.75MG;3.75MG;3.75MG;3.75MG, CAPSULE, EXTENDED RELEASE;ORAL - 5MG;5MG;5MG;5MG, CAPSULE, EXTENDED RELEASE;ORAL - 6.25MG;6.25MG;6.25MG;6.25MG, CAPSULE, EXTENDED RELEASE;ORAL - 7.5MG;7.5MG;7.5MG;7.5MG

CAPSULE, EXTENDED RELEASE;ORAL - 1.25MG;1.25MG;1.25MG;1.25MG
CAPSULE, EXTENDED RELEASE;ORAL - 2.5MG;2.5MG;2.5MG;2.5MG
CAPSULE, EXTENDED RELEASE;ORAL - 3.75MG;3.75MG;3.75MG;3.75MG
CAPSULE, EXTENDED RELEASE;ORAL - 5MG;5MG;5MG;5MG
CAPSULE, EXTENDED RELEASE;ORAL - 6.25MG;6.25MG;6.25MG;6.25MG
CAPSULE, EXTENDED RELEASE;ORAL - 7.5MG;7.5MG;7.5MG;7.5MG

RELATED EXCIPIENT COMPANIES

7 Evonik, 4 Rochem International Inc, 18 SPI Pharma, 2 Seqens, 9 DKSH, 6 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 6 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 29 BASF, 20 Corel Pharma Chem, 5 DFE Pharma, 2 Finar, 9 Gangwal Chemicals, 13 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 2 Nomisma Healthcare, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 6 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 26 Roquette, 8 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 3 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

86 Fillers, Diluents & Binders, 68 Coating Systems & Additives, 47 Controlled & Modified Release, 35 Direct Compression, 33 Disintegrants & Superdisintegrants, 31 Thickeners and Stabilizers, 26 Granulation, 26 Solubilizers, 25 Taste Masking, 19 Chewable & Orodispersible Aids, 16 Lubricants & Glidants, 16 Film Formers & Plasticizers, 14 Co-Processed Excipients, 11 Topical, 11 Parenteral, 9 Empty Capsules, 6 Emulsifying Agents, 5 Coloring Agents, 5 API Stability Enhancers, 4 Vegetarian Capsules, 2 Rheology Modifiers, 1 Surfactant & Foaming Agents

86 Fillers, Diluents & Binders
68 Coating Systems & Additives
47 Controlled & Modified Release
35 Direct Compression
33 Disintegrants & Superdisintegrants
31 Thickeners and Stabilizers
26 Granulation
26 Solubilizers
25 Taste Masking
19 Chewable & Orodispersible Aids
16 Lubricants & Glidants
16 Film Formers & Plasticizers
14 Co-Processed Excipients
11 Topical
11 Parenteral
9 Empty Capsules
6 Emulsifying Agents
5 Coloring Agents
5 API Stability Enhancers
4 Vegetarian Capsules
2 Rheology Modifiers
1 Surfactant & Foaming Agents

DIGITAL CONTENT

25 NEWS #PharmaBuzz

25 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

5 Annual Reports

5 Annual Reports

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

8 US Patents

8 US Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

$ API Ref.Price (USD/KG) : 2,479 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

8 All

01 8TAKEDA PHARMS USA

filter Patent Number Reset all filters

8 All

01 48846100

02 49173857

filter API Patent Reset all filters

8 All

01 8Blank

filter FDF Patent Reset all filters

8 All

01 4Y

02 4Blank

filter Expiration Date Reset all filters

8 All

01 42026-05-12

02 42029-08-24

Product Main Page

01

TAKEDA PHARMS USA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

The Generic Rx Session

Not Confirmed

TAKEDA PHARMS USA

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-05-12

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

US Patent Number : 9173857

Drug Substance Claim :

Drug Product Claim :

Application Number : 22063

Patent Use Code : U-2025

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-05-12

Portfolio PDF

Product Web Link

Digital Content

02

TAKEDA PHARMS USA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

The Generic Rx Session

Not Confirmed

TAKEDA PHARMS USA

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-05-12

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

US Patent Number : 9173857

Drug Substance Claim :

Drug Product Claim :

Application Number : 22063

Patent Use Code : U-2025

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-05-12

Portfolio PDF

Product Web Link

Digital Content

03

TAKEDA PHARMS USA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

The Generic Rx Session

Not Confirmed

TAKEDA PHARMS USA

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-05-12

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

US Patent Number : 9173857

Drug Substance Claim :

Drug Product Claim :

Application Number : 22063

Patent Use Code : U-2025

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-05-12

Portfolio PDF

Product Web Link

Digital Content

04

TAKEDA PHARMS USA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

The Generic Rx Session

Not Confirmed

TAKEDA PHARMS USA

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-05-12

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

US Patent Number : 9173857

Drug Substance Claim :

Drug Product Claim :

Application Number : 22063

Patent Use Code : U-2025

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-05-12

Portfolio PDF

Product Web Link

Digital Content

05

TAKEDA PHARMS USA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

The Generic Rx Session

Not Confirmed

TAKEDA PHARMS USA

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-08-24

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

US Patent Number : 8846100

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22063

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-08-24

Portfolio PDF

Product Web Link

Digital Content

06

TAKEDA PHARMS USA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

The Generic Rx Session

Not Confirmed

TAKEDA PHARMS USA

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-08-24

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

US Patent Number : 8846100

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22063

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-08-24

Portfolio PDF

Product Web Link

Digital Content

07

TAKEDA PHARMS USA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

The Generic Rx Session

Not Confirmed

TAKEDA PHARMS USA

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-08-24

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

US Patent Number : 8846100

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22063

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-08-24

Portfolio PDF

Product Web Link

Digital Content

08

TAKEDA PHARMS USA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

The Generic Rx Session

Not Confirmed

TAKEDA PHARMS USA

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-08-24

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

US Patent Number : 8846100

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22063

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-08-24

Portfolio PDF

Product Web Link

Digital Content

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!